Home  |  Contact

UniProtKB/Swiss-Prot Q9UPI3: Variant p.Leu398Val

Feline leukemia virus subgroup C receptor-related protein 2
Gene: FLVCR2
Variant information

Variant position:  398
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Disease [Disclaimer]
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Leucine (L) to Valine (V) at position 398 (L398V, p.Leu398Val).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Similar physico-chemical property. Both residues are medium size and hydrophobic.
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Involvement in disease:  Proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome (PVHH) [MIM:225790]: A rare prenatally lethal disorder characterized by hydranencephaly, a distinctive glomerular vasculopathy in the central nervous system and retina, and diffuse ischemic lesions of the brain stem, basal ganglia, and spinal cord with calcifications. Hydranencephaly is a condition where the greater portions of the cerebral hemispheres and corpus striatum are replaced by cerebrospinal fluid and glial tissue. {ECO:0000269|PubMed:20206334, ECO:0000269|PubMed:20518025, ECO:0000269|PubMed:20690116}. Note=The disease is caused by mutations affecting the gene represented in this entry.
The name and a short description of the disease associated with the variant. For more information about the disease, the user can refer to OMIM, following the link provided after the disease acronym.

Variant description:  In PVHH.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.

Sequence information

Variant position:  398
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  526
The length of the canonical sequence.

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.




Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

Chain 1 – 526 Feline leukemia virus subgroup C receptor-related protein 2
Transmembrane 386 – 406 Helical

Literature citations

Mutations in FLVCR2 are associated with proliferative vasculopathy and hydranencephaly-hydrocephaly syndrome (Fowler syndrome).
Meyer E.; Ricketts C.; Morgan N.V.; Morris M.R.; Pasha S.; Tee L.J.; Rahman F.; Bazin A.; Bessieres B.; Dechelotte P.; Yacoubi M.T.; Al-Adnani M.; Marton T.; Tannahill D.; Trembath R.C.; Fallet-Bianco C.; Cox P.; Williams D.; Maher E.R.;
Am. J. Hum. Genet. 86:471-478(2010)
Cited for: VARIANTS PVHH ARG-280; VAL-398 AND ARG-430;

Unexpected allelic heterogeneity and spectrum of mutations in Fowler syndrome revealed by next-generation exome sequencing.
Lalonde E.; Albrecht S.; Ha K.C.; Jacob K.; Bolduc N.; Polychronakos C.; Dechelotte P.; Majewski J.; Jabado N.;
Hum. Mutat. 31:918-923(2010)
Cited for: VARIANTS PVHH 110-ASN--PHE-112 DELINS ILE; VAL-326 AND VAL-398;

High-throughput sequencing of a 4.1 Mb linkage interval reveals FLVCR2 deletions and mutations in lethal cerebral vasculopathy.
Thomas S.; Encha-Razavi F.; Devisme L.; Etchevers H.; Bessieres-Grattagliano B.; Goudefroye G.; Elkhartoufi N.; Pateau E.; Ichkou A.; Bonniere M.; Marcorelle P.; Parent P.; Manouvrier S.; Holder M.; Laquerriere A.; Loeuillet L.; Roume J.; Martinovic J.; Mougou-Zerelli S.; Gonzales M.; Meyer V.; Wessner M.; Feysot C.B.; Nitschke P.; Leticee N.; Munnich A.; Lyonnet S.; Wookey P.; Gyapay G.; Foliguet B.; Vekemans M.; Attie-Bitach T.;
Hum. Mutat. 31:1134-1141(2010)
Cited for: VARIANTS PVHH HIS-84; ARG-352; VAL-398; ARG-412 AND MET-430;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.